天康生物(002100) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥4,412,241,435.12, representing a 12.63% increase year-over-year, while the total revenue for the year-to-date reached ¥12,328,880,018.57, up 43.01% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2021 was -¥434,255,970.41, a decrease of 167.45% year-over-year, with a year-to-date net profit of -¥192,859,153.56, down 113.05% compared to the previous year[5] - The total operating revenue for the third quarter reached ¥12,328,880,018.57, an increase of 43.5% compared to ¥8,620,752,350.59 in the same period last year[37] - The company reported a total operating profit (loss) of -36,727,106.21, a stark contrast to the previous operating profit of 1,540,695,224.14[40] - The net profit for the current period is -101,197,342.94, compared to a net profit of 1,514,841,362.12 in the previous period, indicating a significant decline[40] - The total comprehensive income attributable to the parent company owner was -158,326,403.58, compared to 1,477,586,003.68 in the previous period[43] - The basic earnings per share for the current period is -0.18, compared to 1.38 in the previous period, reflecting a decline in profitability[43] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥3,629,302,404.17, reflecting a 73.01% increase compared to the same period last year[5] - The cash flow from operating activities netted 3,629,302,404.17, compared to 2,097,715,885.13 in the previous period, representing an increase of approximately 73.1%[44] - The company’s cash flow from investing activities showed a net outflow of -¥1,242,949,423.18, which was a 238.75% increase in outflow compared to the previous year[12] - The net cash flow from investing activities was -$1.24 billion, compared to -$366.92 million in the previous period[50] - The net cash flow from financing activities was -$1.57 billion, an increase from -$996.88 million year-over-year[50] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥14,125,593,187.89, a decrease of 10.20% from the end of the previous year, while total equity attributable to shareholders was ¥5,633,414,175.65, down 9.63%[7] - The total assets increased to $15.87 billion, reflecting an adjustment of $142.70 million due to the new leasing standards[61] - The total liabilities rose to $9.00 billion, with a notable increase in non-current liabilities by $142.70 million[61] - Total liabilities decreased to ¥7,737,927,143.58 from ¥8,861,606,062.86, a reduction of 12.7%[35] - Shareholders' equity totaled ¥6,387,666,044.31, down from ¥6,867,687,523.05, reflecting a decrease of 7.0%[35] Shareholder Information - The total number of common shareholders at the end of the reporting period was 96,197[17] - The largest shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd., holds 26.38% of shares, totaling 283,929,184 shares[17] - Beijing Rongyuan Baotong Asset Management Partnership holds 6.39% of shares, totaling 68,754,835 shares, with 10,669,513 shares frozen[17] - Xinjiang Tianbang Hongkang Venture Capital Partnership holds 5.81% of shares, totaling 62,580,733 shares[17] - Xinjiang Tianbang Hongkang Venture Capital Partnership holds 20,000,000 shares through a credit securities account[20] - He Sheng holds 4,700,000 shares through a credit securities account[20] Operational Metrics - The company reported a significant increase in accounts receivable, which rose by 72.87% to ¥552,992,588.27, attributed to expanded sales[10] - The company’s inventory decreased by 50.09% to ¥3,004,604,027.87, mainly due to seasonal sales patterns in agricultural products[13] - Total operating costs amounted to ¥12,249,517,556.23, up from ¥7,034,827,366.08, reflecting a significant increase in operational expenses[37] - Cash and cash equivalents increased to ¥3,011,280,484.53 from ¥2,067,234,276.03, representing a growth of 45.5% year-over-year[31] - Accounts receivable rose to ¥552,992,588.27, compared to ¥319,881,376.70, indicating a 72.8% increase[31] - Inventory decreased to ¥3,004,604,027.87 from ¥6,020,026,015.04, a decline of 50.2%[31] - Non-current assets totaled ¥6,170,481,378.89, up from ¥5,032,416,026.65, marking a growth of 22.6%[32] Expenses - The company’s management expenses increased by 44.15% to ¥585,539,002.30, driven by expanded operations and increased share-based payment amortization[12] - The company incurred financial expenses of 149,251,162.29, up from 124,754,901.05, indicating increased borrowing costs[40] - The company’s total tax expenses were 43,439,870.12, compared to 25,404,126.94 in the previous period, indicating higher tax liabilities[40] - Research and development expenses increased slightly to 103,198,682.12 from 102,620,466.88, showing a focus on innovation[40] Stock Issuance - The company received approval for a non-public stock issuance from the Xinjiang Production and Construction Corps State-owned Assets Supervision and Administration Commission on January 18, 2021[21] - The company’s non-public stock issuance application was accepted by the China Securities Regulatory Commission on February 22, 2021[22] - The non-public stock issuance application was approved by the China Securities Regulatory Commission on May 10, 2021[24] - The employee stock ownership plan's lock-up period expired on September 14, 2021, allowing for the release of shares[25] Market Strategy - The company is focusing on expanding its market presence and developing new products to drive future growth[39]